table 3.

Proportion of baseline retinal thickness at each visit by treatment group. Values less than one indicate a decrease in retinal thickness with lower values indicating greater decreases.

Proportion of Baseline within Each Treatment Group*
Estimate (99.87%Confidence interval)† P-value
	Periocular		Intravitreal		Dexamethasone
Week 4	0.78 (0.69, 0.89)	<0.0001	0.58 (0.50, 0.66)	<0.0001	0.56 (0.48, 0.65)	<0.0001
Week 8	0.77 (0.67, 0.89)	<0.0001	0.61 (0.53, 0.70)	<0.0001	0.54 (0.46, 0.63)	<0.0001
Week 12	0.75 (0.64, 0.86)	<0.0001	0.61 (0.54, 0.69)	<0.0001	0.63 (0.53, 0.75)	<0.0001
Week 24	0.68 (0.59, 0.79)	<0.0001	0.64 (0.56, 0.74)	<0.0001	0.61 (0.52, 0.71)	<0.0001
Ratio of the Proportion of Baseline between Treatment Groups
Estimate (99.87%Confidence interval)† P-value
	Superiority Hypotheses			Non-inferiority Hypothesis‡
	Intravitreal/ Periocular		Dexamethasone/ Periocular		Dexamethasone/ Intravitreal
Week 4	0.73 (0.61, 0.88)	<0.0001	0.71 (0.59, 0.86)	<0.0001	0.97 (0.80, 1.18)	n/a
Week 8	0.79 (0.65, 0.96)	<0.0001	0.69 (0.56, 0.86)	<0.0001	0.88 (0.71, 1.08)	n/a
Week 12	0.82 (0.67, 0.98)	0.0003	0.84 (0.67, 1.06)	0.012	1.03 (0.84, 1.27)	n/a
Week 24	0.95 (0.77, 1.16)	0.35	0.89 (0.72, 1.10)	0.07	0.94 (0.77, 1.16)	n/a

^*The percent decline from baseline is 100*(1-proportion of baseline). For example, there is a 23% decrease for periocular, a 39% decrease for intravitreal, and a 46% decrease for dexamethasone at week 8.

^†The two-sided type I error threshold was 0.00132 since recruitment was halted after the single pre-planned interim analysis.

^‡Non-inferiority is evaluated by comparing the upper limit of the 99.87% confidence interval with the pre-defined non-inferiority margin as opposed to p-values, which translates to a one-sided test with a type I error rate of 0.00066. The non-inferiority margin for the comparison between dexamethasone and intravitreal treatment was 1.16, i.e. dexamethasone is considered non-inferior if the upper boundary of the 99.87% confidence interval is less than 1.16.